Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761627 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 494
- Enrollment target
- 20
- Study locations
NCT04761627: Completed Phase 3 study of Psoriasis, sponsored by Amgen.
NCT04761627 is a Phase 3 study of Psoriasis that has completed, run by Amgen. The registered enrollment target is 494 participants, roughly in line with the 485-participant average among 125 other Psoriasis trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04761627, a Phase 3 study of Psoriasis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 494 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.
Primary Outcome
AUCtau from time 0 (week 52) over the dosing interval up to week 64 is presented. Pharmacokinetic (PK) parameters are based on ABP 654 in the switching group and on ustekinumab in the continued-use group.
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG ABP 654
Study Locations (20)
Florida
- Encore Research Group-Jacksonville Center for Clinical Resea - Jacksonville
- Altus Research, Inc. - Lake Worth
- International Dermatology Research, Inc. - Miami
- Leavitt Medical Associates of Florida d/b/a Ameriderm Research - Ormond Beach
- Riverchase Dermatology and Cosmetic Surgery - Pembroke Pines
- Olympian Clinical Research - Tampa
California
- Zenith Research Inc. - Beverly Hills
- Center for Dermatology Clinical Research, Inc. - Fremont
- Quest Dermatology Research - Northridge
- Southern California Dermatology, Inc - Santa Ana
Georgia
- Hamilton Research, LLC - Alpharetta
- Advanced Medical Research PC - Sandy Springs
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Illinois
- Dundee Dermatology - West Dundee
Indiana
- DS Research - Clarksville
Iowa
- Integrated Clinical Trial Services Inc. - West Des Moines
Kansas
- Kansas Medical Clinic, PA - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 3 |
What the finished NCT04761627 record still lists
NCT04761627 is an interventional study that assigns participants to a tested intervention. The registered 494 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 485-participant average among 125 other Psoriasis trials with a reported enrollment target.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT04761627 names 20 study sites across 11 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04761627 about?
NCT04761627 is a clinical study titled "A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT04761627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 494 participants. The study started on 2021-03-24. Estimated completion is 2023-02-28.
What conditions does trial NCT04761627 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04761627?
The interventions under investigation include: Ustekinumab (DRUG), ABP 654 (DRUG).
Who is sponsoring clinical trial NCT04761627?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04761627 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04761627's enrollment target sits among peer trials
494 19th of 125 higher than 107 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI